ARTICLE | Clinical News
ACTI starting renal cancer Phase II
November 13, 2001 8:00 AM UTC
Active Biotech (SSE:ACTI) said it will start by early next month a 45-patient U.K. Phase II trial of its tumor targeted superantigens (TTS) cancer immunotherapy to treat renal cell cancer. ...